Kymera Therapeutics (KYMR) Scheduled to Post Earnings on Wednesday

Kymera Therapeutics (NASDAQ:KYMR) is scheduled to be releasing its earnings data before the market opens on Wednesday, August 7th. Analysts expect Kymera Therapeutics to post earnings of ($0.69) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Kymera Therapeutics Stock Performance

NASDAQ KYMR traded up $1.56 during trading on Tuesday, reaching $41.01. 185,407 shares of the company traded hands, compared to its average volume of 673,767. Kymera Therapeutics has a 1-year low of $9.60 and a 1-year high of $48.70. The company has a market cap of $2.52 billion, a price-to-earnings ratio of -16.23 and a beta of 2.22. The stock’s 50 day moving average price is $36.39 and its two-hundred day moving average price is $36.81.

Insiders Place Their Bets

In other news, insider Jared Gollob sold 23,145 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $45.81, for a total transaction of $1,060,272.45. Following the completion of the sale, the insider now owns 95,470 shares in the company, valued at $4,373,480.70. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, insider Jared Gollob sold 23,145 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $45.81, for a total transaction of $1,060,272.45. Following the completion of the sale, the insider now owns 95,470 shares in the company, valued at approximately $4,373,480.70. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Joanna Horobin sold 8,500 shares of the stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 502,345 shares of company stock valued at $19,279,932. 15.82% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

KYMR has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $46.00 price target on shares of Kymera Therapeutics in a research report on Monday, June 17th. Oppenheimer reaffirmed an “outperform” rating and issued a $52.00 target price on shares of Kymera Therapeutics in a report on Wednesday, July 10th. Finally, B. Riley lifted their price target on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a report on Tuesday, July 9th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $42.60.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.